Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook

GLAUKOS Corp

2022-Q3 EPS reported -$1.43 revenue$211,635,000

Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.
Net loss $27.6M ($0.58 diluted) vs net income $6.2M ($0.13) in prior year, which included $30M litigation settlement.
Non-GAAP net loss $21.3M ($0.45) vs non-GAAP net loss $14.7M ($0.31) in Q3 2021.
Updated 2022 net sales guidance to $278-280M from prior $275-280M; cash and investments $371M.
Glaucoma net sales $53.7M, Corneal Health $17.5M; GAAP gross margin 76%, non-GAAP 84%.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

GLAUKOS Corp reported third quarter ended September 30, 2022 results: revenue $71.3 million, net income $27.6 million, EPS ($0.58) per diluted share. Guidance raised.

Period: third quarter ended September 30, 2022
Revenue: $71.3 million
Net income: $27.6 million
EPS: ($0.58) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlights include: ● Net sales of $71.3 million in Q3 2022. ● Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022. ● Gross margin of approximately 76% and non-GAAP gross margin of

View on SEC.gov

Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-22-015982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.